Please type a plus sign (+) inside this box -	+	
---	---	--

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

10 of

		·
	Complete if Known	
Application Number	09/937,150	
Filing Date	September 21, 2001	
First Named Inventor	Terrence R. Burke, Jr.	
Group Art Unit	1653	
Examiner Name	David Lukton	
Attorney Docket Number	401371/NIH	

U.S. PATENT DOCUMENTS										
		U.S. Patent Docum								
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate				
	A 1	3,906,031		Carpino et al.						
	A 2	4,394,519		Carpino et al.						
	A 3	4,879,398		Getman et al.						
\ \ \	A 4	5,182,263		Danho et al.						
	A 5	5,200,546		Burke, Jr. et al.						
	A 6	5,272,268		Toyoda et al.						
	Α7	5,296,608		Danho et al.	25	6-4				
	A8	5,369,110		Schmidlin et al.	ప్రేక					
	A 9	5,457,114		Stüber et al.		ט ני ני 🔾				
	A10	5,463,062		Hemmerle et al.	. d.	Y				
	A11	5,491,253		Stuk et al.	<u>L</u> 3	6				
	A12	5,508,437		Danho et al.		ريا 21				
17	A13	5,525,733		Novack et al.		2002				
	A14	5,612,370		Atwal /						
	A15	5,580,979		Bachovchin /	S					
	A16	5,587,372		Aszodi et al						
	A17	5,616,776		Stuk et al.						
` /	A18	5,627,283		Stüber et al.						
	A19	5,646,036		Schwall et al.						
X	A20	5,679,842		Kleiper						
	A21	5,686,292		Sonwall et al.						
	A22	5,688,992		Burke, Jr. et al.						
/	A23	5,698,731		Bosetti et al.						
	A24	5,707,624		Nickoloff et al.						
	A25	5,710,129		Lynch et al.						
	A26	5,710,173		Tang et al.						
	A27	5,712,395		App et al.						
,,	A28	5,753,687	1	Mjalli et al						
	A29	5,756,817		Choi et al.						
	A30	5,773,411	<u> </u>	Wells et al						
	A31	5,780,496		Tang et al.						
/	A32	5,786,454		Waksman et al.						
	A33	5,789,427		Chen et al.						
	A34	5,792,771		App et al.						
	A35	5,792,783		Tang et al.						
	A36	5,834,504		Tang et al.						
	A37	5,843,997		Heinz et al.						
	A38	5,849,693		Wells et al.						
 	A39	5,849,742		App et al.		·				
1	A40	5,880,141		Tang et al.						
	A40	0,000,141		rang et al.						

Examiner Signature Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

•	$\overline{}$
Please type a plus sign (+) inside this box ->	-

				Complete if Known		
Substitute for for	m 1449A/B/PTO			Application Number	09/937,150	
INFO	RMATION	DICC	OCUDE	Filing Date	September 21, 2001	
*****				First Named Inventor	Terrence R. Burke, Jr.	
STA	TEMENT B	SY API	PLICANT	Group Art Unit	1653	
	(Use as many she	ets as nece	essary)	Examiner Name	David Lukton	
Sheet	2	of	10	Attomey Docket Number	401371/NIH	

	-	U.S. Patent Docun	nent	J.S. PATENT DOCUMENTS		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
1	A41	5,883,110		Tang et al.		
	A42	5,883,113		Tang et al.		
. 1	A43	5,883,116		Tang et al.		
$\overline{}$	A44	5,886,020		Tang et al.		
	A45	5,886,195		Tang et al.		
T	A46	5,891,917		Tang et al.		
	A47	5,912,183		Comoglio et al.	_4	
X	A48	5,935,993		Tapg et al.		- T
$\neg \vdash$	A49	5,958,957		Andersen et al.		E E
	A50	5,965,558		Mjalli et al.	() J	
1	A 5 1	5,972,978		Andersen et al.		MAY U 9
X	A52	5,981,569		App et al.		50
$\overline{}$	A53	6,037,134	1	Margolis	7	20
1	A54	6,228,986	1	Lanter et al.	رد ئ	/15.5 2002
	A55	6,307,090		Burke et al	60	
			1		3	
		. /				
			1			
			1			
			1			
						<u> </u>
			1			
			<u> </u>			
		······································	-			<u> </u>
			1			1
						· · · · · · · · · · · · · · · · · · ·
		•		-		
				-		†
	·		1			
 			1			
+						
			 		· · · · · · · · · · · · · · · · · · ·	
						†
			1		 	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

•	$\overline{}$
Please type a plus sign (+) inside this box ->	+

•			Complete if Known			
Substitute for form 1449A/B/PTO		Application Number	09/937,150			
INFORMATION DISCLOS	HDE	Filing Date	September 21, 2001	2		
		First Named Inventor	Terrence R. Burke, Jr.	() ()		
STATEMENT BY APPLIC	ANI	Group Art Unit	1653			טב
(Use as many sheets as necessary)		Examiner Name	David Lukton		15	
Sheet 3 of	10	Attorney Docket Number	401371/NIH			()

						<u> </u>	9 . 11
			U.S	S. PATENT DOCUMENTS	Ç ja	2/	V.
		U.S. Patent Docu	ment		3/	200	
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of ੴ Publication ≦⊇	Filing Da Appropr	8 //

				FOREIG	N PATENT DOCUMENTS			
		F	oreign Patent Documer	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
XX.	A56	PCT	WO 94/07913		Dobrusin et al.	04/14/94		
	A57	PCT	WO 95/11917		Bolton et al.	05/04/95		
	A58	PCT	WO 96/23813	1	Patel et al.	08/08/96		
V A	A59	PCT	WO 97/08193		Garcia-Echeverria et al.	03/06/97		
WI	A60	PCT	WO 00/73326		Roller et al.	12/07/00		

		OTHER • NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Trans Yes	No*+
X	A61	Ye et al., "L-O-(2-Malonyl)tyrosine" A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides", J. Med. Chem. Vol. 38, pp. 4270-4275, 1995		
	A62	Burke, Jr., et al., "4'-O-[2-(2-Fluoromalonyl)]-L-tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides", J. Med. Chem., Vol. 39, pp 1021-1027, March 1, 1996		
	A63	Schoepfer et al., "Structure-based Design of Peptidomimetic Ligands of Grb2-SH2 Domain", Bioorganic & Medicinal Chemistry Letters 8, pp. 2865-2870, 1998		
	A 6 4	Yao et al., "Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate- Containing Ligands", J. Med. Chem., Vol. 42, pp. 25-35, 1999		
	A65	Gay et al., "Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility", The Journal of Biological Chemistry, Vol. 274, pp. 23311-23315, August 13, 1999		
	A66	Schoepfer et al., "Highly Potent Inhibitors of the Grb2-SH2 Domain", Bioorganic & Medicinal Chemistry Letters 9, pp. 221-226, 1999		
	A67	Burke, Jr., et al., Monocarboxylic-Based Phosphotyrosyl Mimetics in the Design of Grb2 SH2 Domain Inhibitors", Bioorganic & Medicinal Chemistry Letters 9, pp. 347-352, 1999		
	A68	Gilmer et al., "Peptide Inhibitors of src SH3-SH2-Phosphorprotein Interactions", The Journal of Biological Chemistry, Vol. 269, pp. 31711-31719, December 16, 1994		
V	A69	Charifson et al., "Peptide Ligands of pp60 ^{c-src} SH2 Domains: A Thermodynamic and Structural Study", Biochemistry, Vol. 36, pp. 6283-6293, 1997		
	A 7 0	Liu et al., "Synthesis of L-2,3,5,6-Tetrafluoro-4-(Phosphonomethyl) Phenylalanine, a Novel Non-Hydrolyzable Phosphotyrosine Mimetic and L-4-(Phosphonodifluoromethyl) Phenylalanine", Tetrahedron Letters, Vol. 38, pp. 1389-1392, 1997		

Date Considered Examiner Signature

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	\vdash
Please type a plus sign (*) mside trus dox	

				Complete if Known						
Substitute for for	m 1449A/B/PTO			Application Number	09/937,150	ر نا		· · · · · · · · · · · · · · · · · · ·		
WIE C	DESTINE	NO.	el OCUDE	Filing Date	September 21, 2001		רוב	$\overline{\mathbb{L}}$		
INFORMATION DISCLOSURE				First Named Inventor	Terrence R. Burke, Jr.		-3			
STA	TEMENT BY	' AP	PLICANT	Group Art Unit	1653			()		
	(Use as many sheets	s as nec	cessary)	Examiner Name	David Lukton	اند .	.0	[[]		
Sheet	4	of	10	Attomey Docket Number		.c. . 3	2	. 3		

		<u> </u>	$\frac{2}{2}$	
		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*
	A71	Cleland, "The Meerwein Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Anilines", The Journal of Organic Chemistry", Vo., 34, pp. 744-747, March 1969		
	A72	Gao et al., "Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic, J. Med. Chem., Vol. 43, pp. 911-920, 2000		
	A73	Furet et al., "Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain, J. Med. Chem., Vol. 41, pp. 3442-3449, 1998		
	A74	Tong et al., "Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding", The Journal of Biological Chemistry, Vol. 273, pp. 20238-20242 August 7, 1998		
	A75	Tulasne et al., "The Multisubstrate Docketing Site of the MET Receptor is Dispensable for MET-mediated RAS Signaling and Cell Scattering", Molecular Biology of the Cell, Vol. 10, pp.551-565, March 1999		
V	A76	Kim et al., "Dual Signaling Role of the Protein Tyrosine Phosphotase SHP-2 in Regulating Expression of Acute-Phase Plasma Proteins by Interleukin-6 Cytokine Receptors in Hepatic Cells", Molecular and Cellular Biology, Vol. 19, pp. 5326-5338, Aug. 1999		
H	A77	Nguyen et al., "Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356", The Journal of Biological Chemistry, Vol. 272, pp. 20811-20819, August 15, 1997		
	A78	Maina et al., "Uncoupling of Grb2 from the Met Receptor in Vivo Reveals Complex roles in Muscle Development", Cell, Vol. 87, pp. 531-542, Nov. 1, 1996		
	A79	Ponzetto et al., "Specific Uncoupling of GRB2 from the Met Receptor", The Journal of Biological Chemistry, Vol. 271, pp. 14119-14123, June 14, 1996		
	A80	Ettmayer et al., "Structural and Conformational Requirements for High-Affinity Binding to the SH2 Domain of Grb2", J. Med. Chem., Vol. 42, pp. 971-980, 1999		
	A81	Royal et al., "Differential Requirement of Grb2 and P13-Kinase in HGF/SF-Induced Cell Motility and Tubulogenesis", Journal of Cellular Physiology, Vol. 173, pp. 196-201, 1997		
N	A82	Gao et al., Biorg and Med Chem Lett. <u>10</u> , 923-927 (2000)		L
X	A83	Burke, Jr., et al., "Preparation ofPeptide Synthesis", J. of Synthetic Organic Chem., No. 11, p. 1019, Nov. 11, 1991.		

	<i>L</i>	<u> </u>	ш						
Examiner Signature	X	bund	7	Max	Date Considered	4 -	19	1-09	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	H
--	---

			_	Complete if Known			
Substitute for for	m 1449A/B/PTO			Application Number	09/937,150		
	NOM ATION I	NIC C	N OCUPE	Filing Date	September 21, 2001		
	RMATION I			First Named Inventor	Terrence R. Burke, Jr.		
STA	TEMENT BY	AP	PLICANT	Group Art Unit	1653		
	(Use as many sheet	s as ned	cessary)	Examiner Name	David Lukton		
Sheet	5	of	10	Attorney Docket Number	401371/NIH		

		OTHER - NON PATENT LITERATURE DOCUMENTS	Tran	slation
Examiner	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
X	A84	Burke, Jr., et al., "Potent Inhibition of Grb2 SH2 domain Binding by Non-Phosphate containing Ligands", First Annual Meeting on the Experimental Therapeutics of Human Cancer, June 11-13, 1998, Hood College, Frederick Maryland (Summary)		
	A85	Katunuma et al., "Use of new synthetic substrates for assays of cathepsin L and cathepsin B", J. Biochem. (Tokyo), Vol. 93, pp. 1129-35, 1983 (Abstract only)		
	A86	Burke, Jr., et al., "Enantioselective SynthesisInhibitory Peptides", Tetrahedron, Vol., 54, pp. 9981-9994, 1998		
	A87	Burke, Jr., et al., "Phosphotyrosyl-Based Motifs in the Structure-Based Design of Protein-Tyrosine Kinase-Dependent Signal Transduction Inhibitors", Current Pharmaceutical Design, Vol. 3, pp. 291-304, 1997	E.A. (REC
V	A88	Burke, Jr., et al., "Nonhydrolyzable Phosphotyrosyl Mimetics for the Preparation of Phosphatase-Resistant SH2 Domain Inhibitors", Biochemistry, Vol. 33, pp. 6490-6494, 1994	9 2002	
DK	A89	Ye et al., "L-O-(2-Malonyl)tyrosine (L-OMT) a New Phosphotyrosyl Mimic Suitably Protected for Solid-Phase Synthesis of Signal Transduction Inhibitory Peptides", Tetrahedron Letters, Vol. 36, pp. 4733-4736, 1995		
l	A90	Kuriyan, "Modular Peptide recognition Domains in Eukaryotic Signaling", Annu. Rev. Biophys. Biomol. Struct., Vol. 26, pp. 259-88, 1997		
	A91	Mayer et al., "Functions of SH2 AND SH3 Domains", Protein modules in signal transduction, edited by A. J. Pawson, Berlin, New York, Springer, c1998, pp. 1-22		
	A92	Fry et al., "New insights into protein-tyrosine kinase receptor signaling complexes", Protein Science, Vol. 2, pp. 1785-1797, 1993		
	A93	Levitzki, "Targeting signal transduction for disease therapy", Current Opinion in Cell Biology, Vol. 8, pp. 239-244, 1996	<u></u>	
	A94	Boutin, "Tyrosine Protein Kinase Inhibition and Cancer", Int. J. Biochem., Vol. 26, pp. 1203-1226, 1994		
	A95	Levizski et al., "Tyrosine Kinase Inhibition: An Approach to Drug Development", Science, Vol. 267, pp. 1782-1788, March 24, 1995		ļ
	A96	Lawrence et al., "Protein Kinase Inhibitors: The Tyrosine-specific Protein Kinases", Pharmacol. Ther., Vol. 77, pp. 81-114, 1998		
V	A97	Burke, Jr., et al., "Protein-Tyrosine Phosphatases: Structure, Mechanism, and Inhibitor Discovery", Biopolymers (Peptide Science), Vol., 47, pp. 225-241 (1998)		
XX	A98	Schoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction", Current Opinion in Chemical Biology, Vol. 1, pp. 227-234, 1997		
Examiner Signature	1 1/0	and Lutton Date Considered 4-19-04		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	干
--	---

		•		Complete if Known			
Substitute for fo	m 1449A/B/PTO			Application Number	09/937,150		
INIE	DRAKTION	DIG(N OSLIDE	Filing Date	September 21, 2001		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Terrence R. Burke, Jr.				
STA	IEMENI BA	r AP	PLICANI	Group Art Unit	1653		
	(Use as many sheet	s as nec	cessary)	Examiner Name	David Lukton		
Sheet	6	of	10	Attorney Docket Number	401371/NIH		

		OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Tran	slation	彐
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*	Ŧ
	A99	Waksman et al., "Crystal structure of the phosphotyrosine recognition domain		ł	
		Sh2 of v-src complexed with tyrosine-phosphorylated peptides", Nature, Vol. 358, pp. 646-653, Aug. 20, 1992			
	A100	Waksman et al., "Binding of High Affinity Phosphotyrosyl Peptide to the Src SH2 Domain: Crystal Structures of the Complexed and Peptide-free Forms", Cell, Vol. 72, pp. 779-790, March 12, 1993	TEO		
	A101	Mikol et al., "The Crystal Structures of the SH2 Domain of p56 ^{ick} Complexed with Two Phosphonopeptides Suggest a Gated Peptide Binding Site", J. Mol. Biol. Vol. 246, pp. 344-355, 1995	Y Office	MAY	
	A102	Hatada et al., "Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor", Nature, Vol. 377, pp. 32-38, Sept. 7, 1995	리) ရ	
	A103	Zhou et al., "Solution structure of the Shc SH2 domain complexed with a tyrosine-phosphorylated peptide from the T-cell receptor", Proc. Natl. Acad. Sci., Vol. 92, pp. 7784-7788, August 1995		2502	
X	A104	Narula et al., "Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide", Structure, Vol. 3, 1061-1073, Oct. 15, 1995			
	`A105	Xu et al., "Solution Structure of the Human pp60 ^{c-src} SH2 Domain Complexed with a Phosphorylated Tyrosine Pentapeptide", Biochemistry, Vol. 34, pp. 2107-2121, 1995			
	A106	Tong et al., "Crystal Structures of the Human p56 ^{lck} SH2 Domain in Complex with Two Short Phosphotyrosyl Peptides at 1.0 Å and 1.8 Å Resolution", Academic Press Limited, 10 pages, 1996.			
	A107	Sicheri et al., "Crystal structure of the Src family tyrosine kinase Hck", Nature, Vol. 385, pp. 602-609, Feb. 13, 1997			
	A108	Chen et al., "Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA", Cell, Vol. 93, pp. 827-839, May 29, 1998			
	A109	Songyang et al., "Recognition and specificity in protein tyrosine kinase-medicated signalling", Elsevier Science Ltd., pp. 470-475, 1995			
	A110	Lunney et al., "Structure-Based Design of a Novel Series of Nonpeptide Ligands That Bind to the pp60 ^{src} SH2 Domain", J. Am. Chem. Soc., Vol. 119, pp. 12471-12476, 1997			
	A111	Pacofsky et al., "Potent Dipeptide Inhibitors of the pp60 ^{c-src} SH2-Domain", J. Med. Chem., Vol. 41, pp. 1894-1908, 1998			
	A112	Marseigne et al., "Synthesis of New Amino Acids Mimicking Sulfated and Phosphorylated Tyrosine Residues", J. Org. Chem., Vol. 53, pp. 3621-3624, 1988			
Y K	A113	Domchek et al., "Inhibition of SH2 Domain/Phosphoprotein Association by a Nonhydrolyzable Phosphonopeptide", Biochemistry, Vol. 31, pp. 9865-9870, 1992			
	\overline{A}				 -
Examiner Signature	IXA	and Lallan Date Considered 4-19-04			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	F

				Complete if Known			
Substitute for fo	m 1449A/B/PTO			Application Number	09/937,150		
INITO	RMATION I	nie (N OSLIDE	Filing Date	September 21, 2001		
				First Named Inventor	Terrence R. Burke, Jr.		
STA	TEMENT BY	AP	PLICANI	Group Art Unit	1653		
	(Use as many sheet	s as ne	cessary)	Examiner Name	David Lukton		
Sheet	7	of	10	Attorney Docket Number	401371/NIH		

	-	OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Tran Yes	slation No**
X	A114	Xiao et al., "Syp (SH-PTP2) Is a Positive Mediator of Growth Factor-stimulated Mitogenic Signal Transduction", The Journal of Biological Chemistry, Vol. 269, pp. 21244-21248, August 19, 1994		
	A115	Wange et al., "F ₂ (Pmp) ₂ -TAMς ₃ , a Novel Competitive Inhibitor of the binding of ZAP-70 to the T Cell Antigen Receptor, Blocks Early T Cell Signaling", JBC Online, Vol. 270, pp. 944-948, Jan. 13, 1995		
	A116	Rojas et al., "Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF Receptor The Journal of Biological Chemistry, Vol. 271, pp. 27456-27461, Nov. 1, 1996	MAY	
	A117	Williams et al., "Selective Inhibition of Growth Faxtor-stimulated Mitogenesis by a Cell-permeable Grb2-binding Peptide", The Journal of Biological Chemistry, Vol. 272, pp. 22349-22354, Aug. 29, 1997	C o 2	
	A118	Stankovic, "The Role of 4-Phosphonodifluoromethyl- and 4-Phosphono-Phenylalanine in the Selectivity and Cellular Uptake of SH2 domain Ligands", Bioorganic & Medicinal Chemistry Letters, Vol. 7, pp. 1909-1914, 1997	nn2	
WK.	A119	Mehrotra et al., "a-Dicarbonyls as "Non-Charged" Arginine-Directed Affinity Labels", Bioorganic & Medicinal Chemistry Letters, Vol. 6, pp. 1941-1946, 1996		
	A120	Margolis, "The GRB Family of SH2 domain Proteins", Prog. Biophys. Molec. Biol., Vol. 62, pp. 223-244, 1994		
	A121	Burke, Jr., et al., "Preparation of Fluoro- and Hydroxy-4-(phosphonomethyl)-D,L-phenylalanine Suitably Protected for Solid-Phase Synthesis of Peptides Containing Hydrolytically Stable Analogues of O-Phosphotyrosine", Jour. Of Organic Chemistry, pp. 1336-1340, March 12, 1993		
	A122	Burke, Jr., et al., "Synthesis of 4-Phosphono(difluoromethyl)-D,L-phenyllanine and N-Boc and N-Fmoc Derivatives Suitably Protected for solid-Phase Synthesis of Nonhydrolyzable Phosphotyrosyl Peptide Analogues", Tetrahedron Letters, Vol. 34, pp. 4125-4128, 1993		
	A123	Smyth et al., "Enanthioselective Synthesis of N-Boc and N-Fmoc Protected Diethyl 4-Phosphono(difluoromethyl)-L-Phenylalanine; Agents Suitable for the Solid-Phase Synthesis of Peptides Containing Nonhydrolyzable Analogues of O-Phosphotyrosine", Tetrahedron letters, vol. 35, pp. 551-554, 1994		
	A124	Miller et al., "EPSP Synthase3-Phosphate Mimics", J. Organic & Medicinal Chem. Letters, Vol. 3, No. 7, pp. 1435-1440, 1993.		<u> </u>
XX	A125	"Synthesis andcontaining peptides", Chem. Abs., Vol. 123, No. 257331h, p. 1220, 1995.		

Examiner Signature Date Considered 4 - 19 - 04

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box -	$\overline{+}$
---	----------------

			· ·	Complete if Known		
Substitute for form 1449A/B/PTO				Application Number	09/937,150	
INIEC		DISC	LOCUDE	Filing Date	September 21, 2001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Terrence R. Burke, Jr.	
STA	JEWENI B	Y API	PLICANI	Group Art Unit	1653	
	(Use as many she	ets as nec	essary)	Examiner Name	David Lukton	
Sheet	8	of	10	Attorney Docket Number	401371/NIH	

		OTHER • NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Trans Yes	slation No*+
Q.	A126	Furet et al., "Discovery of 3-Aminobenzyloxycarbonyl as an N-Terminal Group conferring High Affinity to the Minimal Phosphopeptide Sequence Recognized by the Grb2-SH2 Domain", J. Med. Chem., Vol. 40, pp. 3551-3556, 1997		
	A127	Rahuel et al., "Structural Basis for the High Affinity of Amino-Aromatic SH2 Phosphopeptide Ligands", J. Mol. Biol., 279, pp. 1013-1022, 1998		
	A128	Garcia-Echeverria et al., "Potent Antagonists of the SH2 Domain of Grb2: Optimization of the X ₊₁ -Position of 3-Amino-Z-Tyr(PO ₃ H ₂)-X ₌₁ -Asn-NH ₂ ", Journal of Medicinal Chemistry, Vol. 41, pp. 1741-1744, May 21, 1998.	7	28 0
	A129	Rahuel et al., "Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode", Nature Structural Biology, Vol. 3, No. 7, pp. 586-589, July 7, 1996)]
	A130	Oligino et al., "Nonphosphorylated2 Domain", The J. of Biological Chem., Vol. 272, No. 46, pp. 29046-29052, November 14, 1997	ال التي الله الاستالية	Í
$\langle \rangle$	A131	Allen et al., "Tritiated Peptides. Part 15. Synthesis of Tritium Labelled Biologically Active Analogues of Somatostatin", J. Chem. Soc., Perkin Trans. 1, pp. 989-1003, 1986	ED	
	A132	Ben-Levy et al., "A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP Kinase pathway", The EMBO Journal, Vol. 13, pp. 3302-3311, 1994		
	A133	Dankort et al., Distinct Tyrosine Autophosphorylation Sites Negatively and Positively Modulate New-Mediated Transformation", Molecular and Cellular Biology, Vol. 17, pp. 5410-5425, Sept. 1997		
	A134	Ma et al., "Bcr phosphorylated on tyrosine 177 binds Grb2", Oncogene, Vol. 14, pp. 2367-2372, 1997		
	A135	DiFiore et al., "Overexpression of the Human EGF Receptor confers an EGF- Dependent Transformed Phenotype to NIH 3T3 Cells", Cell, Vol. 51, pp. 1063-1070, Dec. 24, 1987		
	A136	Hudziak et al, "Increased expression of the putative growth factor receptor p185 ^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells", Proc. Natl. Acad. Sci., Vol. 84, pp. 7159-7163, October 1987		
	A137	Kraus et al., "Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cells lines by different molecular mechanisms", The EMBO Journal, Vol. 6, pp. 605-610, 1987		
	A138	Sastry et al., "Quantitative analysis of Grb2-Sos1 interaction: the N-terminal SH3 domain of Grb2 mediates affinity", Oncogene, 11, pp. 1107-1112, 1995		

Date Examiner Considered Signature

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

		_
Please type a plus sign (+) inside this box	14	L
1 18830 type a piece aign () maint and a		

					Complete if Known	
Substitute for fo	rm 1449A/B/PTO			Application Number	09/937,150	
INIEC	ADMATION.	חופר	I OSLIDE	Filing Date	September 21, 2001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Terrence R. Burke, Jr.	
STA	TEMENT B	Y AP	PLICANI	Group Art Unit	1653	
	(Use as many shee	ts as ned	cessary)	Examiner Name	David Lukton	
Sheet	9	of	. 10	Attorney Docket Number	401371/NIH	

		OTHER - NON PATENT LITERATURE DOCUMENTS	Tana	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
WP	A139	Searles, The Reaction of Trimethylene Oxide with Grignard Reagents and Organolithium Compounds", J. Amer. Chem. Soc., Vol. 73, pp. 124-125, 1951		
	A140	Fretz et al., "Targeting a Hydrophobic Patch on the Surface of the Grb2-SH2 Domain", 15 th Amer. Peptide Symposium, Nashville, TN, June 1997, Abstract No. P422		
	A141	Fixman et al., "Efficient CellularProteins, Cb1 and Gab1", The J. of Biological Chem., Vol. 272, No. 32, pp. 20167-20172, August 8, 1997	5	
	A142	Tari et al., "Inhibition of Grb2Leukemic Cells", Biochemical and Biophysical Research Communications, Vol. 235, pp. 383-388, Article No. RC976791, 1997	lV.	-]
	A143	Xie et al., "Dominant-negative MutantsRat HER-2/Neu", The J. of Biological Chem. 5.7 Vol. 270, No. 51, pp. 30717-30724, Dec. 22, 1995.	AY C	
	A144	Maignan et al., "Crystal Structure of the Mammalian Grb2 Adaptor", Science, Vol. 268, pp. 291-293, April 14, 1995	5. 2002	
	A145	Saltiel et al., "Targeting signal transduction in the discovery of antiproliferative drugs" Chemistry & Biology, Vol. 3, No. 11, pp. 887-893, Nov. 1996.	12	
	A146	McNemar et al., "Thermodynamic andBinding to Grb2-SH2:, Biochemistry, Vol. 36, pp. 10006-10014, 1997		
	A147	Ogura et al., "Conformation of anGrb2 SH2 domain", J. of Biomolecular NMR, Vol. 10, pp. 273-278, 1997		
	A148	Gay et al., "Dual Specificity ofPeptide Ligands", Biochemistry, Vol. 36, pp. 5712-5718, 1997		
	A149	Bobko et al., "CD45 Proteinlrreversible Inhibitors", Bioorganic & Medicinal Chem. Letters, Vol. 5, No. 4, pp. 353-356, 1995		
	A150	Burke et al., "Conformationally Constrained2 Domain Inhibitors", J. Med. Chem., Vol. 38, pp. 1386-1396, 1995.		
	A151	Chemical Abstracts, Vol. 122, p. 424, 1995 (Abs. No. 258899)		
	A152	Gordeev et al., "N-a-Fmoc-4-Phosphono(difluoromethyl)-L-phenylalanine:into Peptides", Tetrahedron Letters, Vol. 35, pp. 7585-7588, 1994.		
	A153	Kitas et al., "Synthesis of O-PhosphotyrosineDeportection Procedures", J. Org. Chem., Vol. 55, pp. 4181-4187, 1990		
	A154	Chemical Abstracts, Vol. 124, No. 1, p. 1004, 1996 (Abs. No. 9413)		
	A155	Morelock et al., "Determination of ReceptorPhosphotyrosyl Peptides", J. of Med. Chem., Vol. 38, pp. 1309-1318.		
	A156	Shahripour et al., "Novel PhosphotyrosineDomain", Bioorganic & Medicinal Chem. Letters, Vol. 6, No. 11, pp. 1209-1214, 1996.		
XX	A157	Rojas et al., "An AlternativeSH2 Domain", Biochemical and Biophysical Research Communications, Vol. 234, pp. 675-680, 1997		

Examiner Signature Date Considered 4 - 19 - 0 4

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

•	
Please type a plus sign (+) inside this box ->	╌
Please type a plus sign (+) triside tris box	"

				Complete if Known		
Substitute for fo	orm 1449A/B/PTO			Application Number	09/937,150	
11.50	SOMATION	DICC	1 OCUPE	Filing Date	September 21, 2001	
	ORMATION			First Named Inventor	Terrence R. Burke, Jr.	
STA	TEMENT B	Y AP	PLICANI	Group Art Unit	1653	
	(Use as many shee	ets as nec	essary)	Examiner Name	David Lukton	
Sheet	10	of	10	Attorney Docket Number	401371/NIH	

			U.S.	PATENT DOCUMENTS		
		U.S. Patent Docu	ment			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
			J			
			<u> </u>			
			 _ _ _ _ _ _ _ _ _ _			
			<u> </u>			
	ļ					
			<u> </u>			
			<u> </u>			
			ļļ.		15C	-11
					<u> </u>	
			 		77000	\
	ļ		<u> </u>		CENTED.	
		<u> </u>			 	
			<u> </u>	•		
						3 17
			 		6.3	
			 		300	
	ļ		 		 	
		····	 			
						<u> </u>
	1					

	***			FOREIGN F	PATENT DOCUMENTS			
_		Fo	reign Patent Docume	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
				 		 	ļ <u>-</u>	-
				+ +			 	

		OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
XX	A158	Jiang et al. "Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer", Critical Reviews in Oncology/Hematology, 29:209-248 (1999)		
	A159	Kim et al., "FEBS Lett., 453, 174-178, 1999		
		1		
				l,

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).